Cargando…
Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer
BACKGROUND: The aim of this study is to investigate the impact of (18)F-FDG PET/CT on prognosis of stage II invasive ductal carcinoma (IDC) of the breast primarily treated with surgery. METHODS: The clinical records of 297 consecutive IDC with preoperative PET/CT and pathologically staged II in surg...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811771/ https://www.ncbi.nlm.nih.gov/pubmed/36600314 http://dx.doi.org/10.1186/s40644-022-00519-6 |
_version_ | 1784863595829395456 |
---|---|
author | Park, Hye Lim Lee, Sea-Won Hong, Ji Hyung Lee, Jieun Lee, Ahwon Kwon, Soo Jin Park, Sonya Youngju Yoo, Ie Ryung |
author_facet | Park, Hye Lim Lee, Sea-Won Hong, Ji Hyung Lee, Jieun Lee, Ahwon Kwon, Soo Jin Park, Sonya Youngju Yoo, Ie Ryung |
author_sort | Park, Hye Lim |
collection | PubMed |
description | BACKGROUND: The aim of this study is to investigate the impact of (18)F-FDG PET/CT on prognosis of stage II invasive ductal carcinoma (IDC) of the breast primarily treated with surgery. METHODS: The clinical records of 297 consecutive IDC with preoperative PET/CT and pathologically staged II in surgery from 2013 to 2017 were retrospectively reviewed. The maximum standardized uptake value (SUVmax), peak standardized uptake value (SUVpeak), tumor-to-liver ratio (TLR), and metabolic tumor volume (MTV) were measured. Association of clinicopathologic factors (age, T stage, N stage, AJCC pathologic stage of IIA or IIB, pathologic prognostic stage, grade, hormonal receptor status, HER2 status, Ki-67, and adjuvant therapy) and PET parameters with DFS was assessed using the Cox proportional hazards model. RESULTS: There were 35 recurrences and 10 deaths at a median follow-up of 49 months (range 0.8 ~ 87.3). All PET parameters were significantly associated with DFS in univariate analysis but in multivariate analysis, SUVpeak was the only factor significantly associated with DFS (hazard ratio 2.58, 95% confidence interval 1.29–5.15, P = 0.007). In cohorts with higher values of SUVpeak or TLR, patients who received adjuvant chemotherapy had significantly superior DFS. CONCLUSION: Metabolic parameters derived from preoperative PET/CT was significantly associated with recurrence in stage II IDC primarily treated with surgery. PET/CT can be a powerful prognostic tool in conjunction with novel staging systems and current biomarkers for patients undergoing contemporary therapy. Our results urge to reconsider the currently underestimated value of PET/CT confined to diagnostic aspect and to newly recognize its prognostic impact in these intermediate-risk breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-022-00519-6. |
format | Online Article Text |
id | pubmed-9811771 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98117712023-01-05 Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer Park, Hye Lim Lee, Sea-Won Hong, Ji Hyung Lee, Jieun Lee, Ahwon Kwon, Soo Jin Park, Sonya Youngju Yoo, Ie Ryung Cancer Imaging Research Article BACKGROUND: The aim of this study is to investigate the impact of (18)F-FDG PET/CT on prognosis of stage II invasive ductal carcinoma (IDC) of the breast primarily treated with surgery. METHODS: The clinical records of 297 consecutive IDC with preoperative PET/CT and pathologically staged II in surgery from 2013 to 2017 were retrospectively reviewed. The maximum standardized uptake value (SUVmax), peak standardized uptake value (SUVpeak), tumor-to-liver ratio (TLR), and metabolic tumor volume (MTV) were measured. Association of clinicopathologic factors (age, T stage, N stage, AJCC pathologic stage of IIA or IIB, pathologic prognostic stage, grade, hormonal receptor status, HER2 status, Ki-67, and adjuvant therapy) and PET parameters with DFS was assessed using the Cox proportional hazards model. RESULTS: There were 35 recurrences and 10 deaths at a median follow-up of 49 months (range 0.8 ~ 87.3). All PET parameters were significantly associated with DFS in univariate analysis but in multivariate analysis, SUVpeak was the only factor significantly associated with DFS (hazard ratio 2.58, 95% confidence interval 1.29–5.15, P = 0.007). In cohorts with higher values of SUVpeak or TLR, patients who received adjuvant chemotherapy had significantly superior DFS. CONCLUSION: Metabolic parameters derived from preoperative PET/CT was significantly associated with recurrence in stage II IDC primarily treated with surgery. PET/CT can be a powerful prognostic tool in conjunction with novel staging systems and current biomarkers for patients undergoing contemporary therapy. Our results urge to reconsider the currently underestimated value of PET/CT confined to diagnostic aspect and to newly recognize its prognostic impact in these intermediate-risk breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-022-00519-6. BioMed Central 2023-01-04 /pmc/articles/PMC9811771/ /pubmed/36600314 http://dx.doi.org/10.1186/s40644-022-00519-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Park, Hye Lim Lee, Sea-Won Hong, Ji Hyung Lee, Jieun Lee, Ahwon Kwon, Soo Jin Park, Sonya Youngju Yoo, Ie Ryung Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer |
title | Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer |
title_full | Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer |
title_fullStr | Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer |
title_full_unstemmed | Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer |
title_short | Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer |
title_sort | prognostic impact of (18)f-fdg pet/ct in pathologic stage ii invasive ductal carcinoma of the breast: re-illuminating the value of pet/ct in intermediate-risk breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811771/ https://www.ncbi.nlm.nih.gov/pubmed/36600314 http://dx.doi.org/10.1186/s40644-022-00519-6 |
work_keys_str_mv | AT parkhyelim prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer AT leeseawon prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer AT hongjihyung prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer AT leejieun prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer AT leeahwon prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer AT kwonsoojin prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer AT parksonyayoungju prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer AT yooieryung prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer |